Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial
Hedy L. Kindler, Silvia Novello, Alessandra Bearz, Giovanni L. Ceresoli, Joachim G.J.V. Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Jennens, Luana Calabrò, Jacobus A. Burgers, Armando Santoro, Susana Cedrés, Piotr Serwatowski, Santiago Ponce, Jan P. Van Meerbeeck, Anna K. Nowak, George Blumenschein, Jonathan M. SiegelLinda Kasten, Karl Köchert, Annette O. Walter, Barrett H. Childs, Cem Elbi, Raffit Hassan, Dean A. Fennell
Dive into the research topics of 'Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial'. Together they form a unique fingerprint.